These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

239 related articles for article (PubMed ID: 23996800)

  • 1. Triacetin-based acetate supplementation as a chemotherapeutic adjuvant therapy in glioma.
    Tsen AR; Long PM; Driscoll HE; Davies MT; Teasdale BA; Penar PL; Pendlebury WW; Spees JL; Lawler SE; Viapiano MS; Jaworski DM
    Int J Cancer; 2014 Mar; 134(6):1300-10. PubMed ID: 23996800
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Acetate supplementation as a means of inducing glioblastoma stem-like cell growth arrest.
    Long PM; Tighe SW; Driscoll HE; Fortner KA; Viapiano MS; Jaworski DM
    J Cell Physiol; 2015 Aug; 230(8):1929-43. PubMed ID: 25573156
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Acetate supplementation induces growth arrest of NG2/PDGFRα-positive oligodendroglioma-derived tumor-initiating cells.
    Long PM; Tighe SW; Driscoll HE; Moffett JR; Namboodiri AM; Viapiano MS; Lawler SE; Jaworski DM
    PLoS One; 2013; 8(11):e80714. PubMed ID: 24278309
    [TBL] [Abstract][Full Text] [Related]  

  • 4. N-acetylaspartate (NAA) and N-acetylaspartylglutamate (NAAG) promote growth and inhibit differentiation of glioma stem-like cells.
    Long PM; Moffett JR; Namboodiri AMA; Viapiano MS; Lawler SE; Jaworski DM
    J Biol Chem; 2013 Sep; 288(36):26188-26200. PubMed ID: 23884408
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A novel drug conjugate, NEO212, targeting proneural and mesenchymal subtypes of patient-derived glioma cancer stem cells.
    Jhaveri N; Agasse F; Armstrong D; Peng L; Commins D; Wang W; Rosenstein-Sisson R; Vaikari VP; Santiago SV; Santos T; Chen L; Schönthal AH; Chen TC; Hofman FM
    Cancer Lett; 2016 Feb; 371(2):240-50. PubMed ID: 26683773
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neural stem/progenitors and glioma stem-like cells have differential sensitivity to chemotherapy.
    Gong X; Schwartz PH; Linskey ME; Bota DA
    Neurology; 2011 Mar; 76(13):1126-34. PubMed ID: 21346220
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Temozolomide decreases invasion of glioma stem cells by down-regulating TGF-β2.
    Zhang D; Jing Z; Qiu B; Wu A; Wang Y
    Oncol Rep; 2011 Oct; 26(4):901-8. PubMed ID: 21725605
    [TBL] [Abstract][Full Text] [Related]  

  • 8. N-acetyl l-aspartate and Triacetin modulate tumor suppressor MicroRNA and class I and II HDAC gene expression induce apoptosis in Glioblastoma cancer cells in vitro.
    Mekala JR; Kurappalli RK; Ramalingam P; Moparthi NR
    Life Sci; 2021 Dec; 286():120024. PubMed ID: 34626605
    [TBL] [Abstract][Full Text] [Related]  

  • 9. NEO212 Inhibits Migration and Invasion of Glioma Stem Cells.
    Marín-Ramos NI; Thein TZ; Cho HY; Swenson SD; Wang W; Schönthal AH; Chen TC; Hofman FM
    Mol Cancer Ther; 2018 Mar; 17(3):625-637. PubMed ID: 29440289
    [TBL] [Abstract][Full Text] [Related]  

  • 10. ABT-888 enhances cytotoxic effects of temozolomide independent of MGMT status in serum free cultured glioma cells.
    Balvers RK; Lamfers ML; Kloezeman JJ; Kleijn A; Berghauser Pont LM; Dirven CM; Leenstra S
    J Transl Med; 2015 Feb; 13():74. PubMed ID: 25886061
    [TBL] [Abstract][Full Text] [Related]  

  • 11. MELK-dependent FOXM1 phosphorylation is essential for proliferation of glioma stem cells.
    Joshi K; Banasavadi-Siddegowda Y; Mo X; Kim SH; Mao P; Kig C; Nardini D; Sobol RW; Chow LM; Kornblum HI; Waclaw R; Beullens M; Nakano I
    Stem Cells; 2013 Jun; 31(6):1051-63. PubMed ID: 23404835
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Progress toward acetate supplementation therapy for Canavan disease: glyceryl triacetate administration increases acetate, but not N-acetylaspartate, levels in brain.
    Mathew R; Arun P; Madhavarao CN; Moffett JR; Namboodiri MA
    J Pharmacol Exp Ther; 2005 Oct; 315(1):297-303. PubMed ID: 16002461
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Interferon-α/β enhances temozolomide activity against MGMT-positive glioma stem-like cells.
    Shen D; Guo CC; Wang J; Qiu ZK; Sai K; Yang QY; Chen YS; Chen FR; Wang J; Panasci L; Chen ZP
    Oncol Rep; 2015 Nov; 34(5):2715-21. PubMed ID: 26329778
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Proteasome inhibition with bortezomib induces cell death in GBM stem-like cells and temozolomide-resistant glioma cell lines, but stimulates GBM stem-like cells' VEGF production and angiogenesis.
    Bota DA; Alexandru D; Keir ST; Bigner D; Vredenburgh J; Friedman HS
    J Neurosurg; 2013 Dec; 119(6):1415-23. PubMed ID: 24093630
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term temozolomide treatment induces marked amino metabolism modifications and an increase in TMZ sensitivity in Hs683 oligodendroglioma cells.
    Lamoral-Theys D; Le Mercier M; Le Calvé B; Rynkowski MA; Bruyère C; Decaestecker C; Haibe-Kains B; Bontempi G; Dubois J; Lefranc F; Kiss R
    Neoplasia; 2010 Jan; 12(1):69-79. PubMed ID: 20072655
    [TBL] [Abstract][Full Text] [Related]  

  • 16. EMAP-II sensitize U87MG and glioma stem-like cells to temozolomide via induction of autophagy-mediated cell death and G2/M arrest.
    Yu Q; Liu L; Wang P; Yao Y; Xue Y; Liu Y
    Cell Cycle; 2017 Jun; 16(11):1085-1092. PubMed ID: 28436750
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of aberrant p53 function on temozolomide sensitivity of glioma cell lines and brain tumor initiating cells from glioblastoma.
    Blough MD; Beauchamp DC; Westgate MR; Kelly JJ; Cairncross JG
    J Neurooncol; 2011 Mar; 102(1):1-7. PubMed ID: 20593219
    [TBL] [Abstract][Full Text] [Related]  

  • 18. YB-1 dependent oncolytic adenovirus efficiently inhibits tumor growth of glioma cancer stem like cells.
    Mantwill K; Naumann U; Seznec J; Girbinger V; Lage H; Surowiak P; Beier D; Mittelbronn M; Schlegel J; Holm PS
    J Transl Med; 2013 Sep; 11():216. PubMed ID: 24044901
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bortezomib inhibits growth and sensitizes glioma to temozolomide (TMZ) via down-regulating the FOXM1-Survivin axis.
    Tang JH; Yang L; Chen JX; Li QR; Zhu LR; Xu QF; Huang GH; Zhang ZX; Xiang Y; Du L; Zhou Z; Lv SQ
    Cancer Commun (Lond); 2019 Dec; 39(1):81. PubMed ID: 31796105
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A safety trial of high dose glyceryl triacetate for Canavan disease.
    Segel R; Anikster Y; Zevin S; Steinberg A; Gahl WA; Fisher D; Staretz-Chacham O; Zimran A; Altarescu G
    Mol Genet Metab; 2011 Jul; 103(3):203-6. PubMed ID: 21474353
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.